These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16432270)

  • 21. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
    Strain EC; Moody DE; Stoller KB; Walsh SL; Bigelow GE
    Drug Alcohol Depend; 2004 Apr; 74(1):37-43. PubMed ID: 15072805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
    McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.
    Fischer A; Jönsson M; Hjelmström P
    Drug Dev Ind Pharm; 2015 Jan; 41(1):79-84. PubMed ID: 24099551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration.
    Robertson SA; Lascelles BD; Taylor PM; Sear JW
    J Vet Pharmacol Ther; 2005 Oct; 28(5):453-60. PubMed ID: 16207308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.
    Wesson DR
    J Psychoactive Drugs; 2004 May; Suppl 2():119-28. PubMed ID: 15279124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.
    Kim HK; Smiddy M; Hoffman RS; Nelson LS
    Pediatrics; 2012 Dec; 130(6):e1700-3. PubMed ID: 23129079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids.
    Mutschler NH; Stephen BJ; Teoh SK; Mendelson JH; Mello NK
    Nicotine Tob Res; 2002 May; 4(2):223-8. PubMed ID: 12028854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine in combination with naloxone at a ratio of 15:1 does not enhance antinociception from buprenorphine in healthy cats.
    Slingsby LS; Murrell JC; Taylor PM
    Vet J; 2012 Jun; 192(3):523-4. PubMed ID: 22030474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.
    Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R
    Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing surveillance of buprenorphine.
    Ray R; Pal H; Kumar R; Maulick P; Mangla R
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):615-9. PubMed ID: 15362084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.
    Lintzeris N; Mitchell TB; Bond AJ; Nestor L; Strang J
    Drug Alcohol Depend; 2007 Dec; 91(2-3):187-94. PubMed ID: 17624687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro and in-vivo characterization of a buprenorphine delivery system.
    Kleppner SR; Patel R; McDonough J; Costantini LC
    J Pharm Pharmacol; 2006 Mar; 58(3):295-302. PubMed ID: 16536895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
    Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
    Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.
    Comer SD; Collins ED; Fischman MW
    Psychopharmacology (Berl); 2001 Feb; 154(1):28-37. PubMed ID: 11292003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
    Walsh SL; Preston KL; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
    Umbricht A; Huestis MA; Cone EJ; Preston KL
    J Clin Psychopharmacol; 2004 Oct; 24(5):479-87. PubMed ID: 15349002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.